Genmab A/S (OTCMKTS:GNMSF) Sets New 12-Month High - Here's Why

Key Points

• Genmab A/S shares reached a new 52-week high of $285.00, marking a significant increase from the previous close of $272.30 and demonstrating a 4.7% rise in a single trading session.
• The company reported earnings of $5.42 per share for the last quarter, surpassing analyst expectations of $3.99, although revenue fell short of predictions at $925 million.
• Genmab specializes in developing antibody therapeutics for cancer, with notable products including DARZALEX for multiple myeloma and teprotumumab for thyroid eye disease.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) reached a new 52-week high on Friday . The company traded as high as $285.00 and last traded at $285.00, with a volume of 445 shares changing hands. The stock had previously closed at $272.30.

Genmab A/S Stock Up 4.7%

The business has a fifty day simple moving average of $240.28 and a two-hundred day simple moving average of $216.12. The company has a market capitalization of $18.83 billion, a price-to-earnings ratio of 14.31 and a beta of 0.90.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $5.42 earnings per share for the quarter, beating analysts' consensus estimates of $3.99 by $1.43. The company had revenue of $925.00 million for the quarter, compared to the consensus estimate of $949.06 million. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.